CSF1R and B-cell chronic lymphocytic leukemia: Ultimately, these results suggest a treatment strategy whereby CSF1R+/CD14+ cells can be chemically targeted by highly selective CSF1R inhibitors, and that this targeting deprives CLL cells of crucial microenvironmental support.